Abstract
Background Adolescent suicide is a major health problem in the US marked by a recent increase in Black/African American youth suicide trends. While genetic factors partly account for familial transmission of suicidal behavior, it is not clear whether polygenic risk scores of suicide attempt have clinical utility in youth suicide risk classification.
Objectives To evaluate the contribution of a polygenic risk score for suicide attempt (PRS-SA) in explaining variance in suicide attempt by early adolescence.
Methods We studied N=5,214 non-related Black and White youth from the Adolescent Brain Cognitive Development (ABCD) Study (ages 8.9-13.8 years) who were evaluated between 2016 and 2021. Regression models tested associations between PRS-SA and parental history of suicide attempt/death with youth-reported suicide attempt. Covariates included age, sex, and race.
Results Over three waves of assessments, 182 youth (3.5%) reported a past suicide attempt, with Black youth reporting significantly more suicide attempts than their White counterparts (6.1% vs 2.8%, P<.001). PRS-SA was associated with suicide attempt (odds ratio [OR]=1.3, 95% confidence interval [CI] 1.1-1.5, P=.001). Inclusion of PRS-SA explained 2.7% of the variance in suicide attempts, significantly more than the base model including only age, sex and race, which explained 1.9% of the variance (P=.001). Parental history of suicide attempt/death was also associated with youth suicide attempt (OR=2.9, 95%CI 1.9-4.4, P<.001). Addition of PRS-SA to the model that included parental history significantly increased the variance explained from 3.3% to 4% (P=.002).
Conclusions Findings suggest that PRS-SA may be useful for suicide risk classification in diverse youth.
Contribution to the Field Statement Adolescent suicidal behavior is a major health problem, with suicide being the 2nd leading cause of death in youth. Research that improves our understanding regarding drivers of suicide risk in youth can inform youth suicide prevention strategies. Family history of suicide is an established risk factor for youth suicidal behavior. Current methods in psychiatric genetics allow calculation of polygenic risk scores that represent genetic liability to specific conditions. It is not clear whether polygenic risk score of suicide attempt can assist in risk classification, beyond family history. In this work, we show that in a sample of 5,214 youth ages 9-13, of which 3.5% reported past suicide attempt, polygenic score of suicide attempt was associated with youth suicide attempt. This association additively explained variance over and above parental history of suicide attempt/death. Findings make a case for the potential utility of incorporating polygenic risk scores as part of suicide attempt risk classification in youth, and suggest that polygenic scores may reveal genetic liability that is not captured by family history of suicide.
Competing Interest Statement
Dr Barzilay serves on the scientific board and receives consulting fees from Taliaz Health and Zynerba Pharmaceuticals and reports stock ownership in Taliaz Health, with no conflict of interest relevant to this work. Elina Visoki spouse is a shareholder and executive in Kidas, with no conflict of interest relevant to this work. In the past 3 years, Dr. Daskalakis has been a consultant for Sunovion Pharmaceuticals and is on the scientific advisory board for Sentio Solutions and Circular Genomics for unrelated work. All other authors have no conflicts of interest to declare.
Funding Statement
This study was supported by the National Institute of Mental Health grants K23MH120437 (RB), R21MH123916 (RB), and the Lifespan Brain Institute of Childrens Hospital of Philadelphia and Penn Medicine, University of Pennsylvania. The funding organization had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The ABCD Study protocol was approved by the University of California, San Diego Institutional Review Board (IRB), and the current analysis was exempted from a full review by University of Pennsylvania IRB.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data used in the preparation of this article were obtained from the ABCD Study (https://abcdstudy.org), held in the NIMH Data Archive.
